Amgen's stock experienced a decline following a warning from Kissei Pharmaceutical regarding potential liver risks associated with its drug Tavneos. The alert raised concerns among investors about the safety profile of the medication, which is used to treat certain autoimmune conditions. As a result, market reactions reflected apprehension over the implications for Amgen's product portfolio and future sales. The situation underscores the importance of ongoing safety evaluations in the pharmaceutical industry.
Related Articles
Don't miss out on breaking stories and in-depth articles.